Image Source: Global Prime News
Vaishali Pharma Limited has approved a preferential allotment of up to 61.23 lakh equity shares at Rs. 20 each, aggregating Rs. 12.25 crore. The issue will be executed via a share swap with Kesar Pharma Limited, subject to shareholder and regulatory approvals.
Show more
Vaishali Pharma Limited, in its board meeting held on 13 February 2026, announced a significant preferential issue aimed at strengthening its strategic position through an equity swap arrangement.
Key Highlights
-
The board approved issuance of up to 61,23,000 fully paid equity shares of face value Rs. 2 each at Rs. 20 per share, including a premium of Rs. 18 per share.
-
The total value of the preferential issue aggregates to Rs. 12.25 crore.
-
Shares will be allotted to non-promoter investors on a preferential basis, in one or more tranches.
-
The issue will be executed through a swap of shares of Kesar Pharma Limited, discharging consideration for Vaishali Pharma’s subscription to 21,52,575 equity shares of Kesar Pharma at Rs. 56.89 per share.
-
The preferential issue remains subject to shareholder approval at the upcoming general meeting and necessary statutory and regulatory clearances.
-
The board has fixed 13 February 2026 as the relevant date under SEBI ICDR Regulations for determining the floor price of the issue.
Sources: Bombay Stock Exchange (BSE) filing, SEBI ICDR Regulations.
Stay Ahead – Explore Now!
Fitch Affirms Ratings of 15 APAC Engineering & Construction Firms After Criteria Update
Advertisement
STORIES YOU MAY LIKE
Updated: February 13, 2026 17:00
Image Source: WOWNEWS24X7
Updated: February 12, 2026 17:33
Image Source: FINIEN
Updated: February 11, 2026 18:03
Advertisement